ReadYourDNA

Linagliptin (Tradjenta)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Linagliptin

What it is

Linagliptin is a DPP-4 inhibitor: it blocks the enzyme that breaks down incretins, gut hormones such as GLP-1 that tell the pancreas to release insulin after a meal. It is used for type 2 diabetes. Unlike most medicines of its group, it is cleared mainly through bile rather than the kidneys, so it is used without change in kidney disease. It is sold as Tradjenta and Trajenta.

How genes come into it

Linagliptin is mostly excreted unchanged in bile, with little broken down by liver enzymes. Studies have looked at genes of the incretin system (DPP4, GLP1R) and diabetes genes such as KCNJ11, WFS1 and TCF7L2 for how much blood sugar fell. The findings come from single or a few studies, and there is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Linagliptin. Upload your DNA file to see which of these rows apply to you.

Response (14 findings)

Studies of how well it worked in people carrying a variant.

GLP1R rs3765467: Genotypes AA + AG is associated with increased clinical benefit to gemigliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.

KCNJ11 rs2285676: Genotype GG is associated with increased clinical benefit to linagliptin, sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.

PRKD1 rs57803087: Allele G is associated with increased response to linagliptin, saxagliptin, sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to allele A.

TCF7L2 rs7903146: Genotypes CC + CT is associated with increased clinical benefit to linagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype TT.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

DPP-4 Inhibitors (class) (DPP-4 Inhibitors)

Galvus (DPP-4 Inhibitors)

Januvia (DPP-4 Inhibitors)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com